24/7 Wall St. has put together a preview of a few of the most anticipated quarterly reports due this week, including Altria, Ford, General Electric and Starbucks
Philip Morris reported earnings and revenues that beat second-quarter estimates. Recent FDA approval of the company's IQOS products have boosted share prices as well.
Marijuana stocks have suffered a terrible beating in the past year or so. Here's a look at six former high-flyers and their prospects for a recovery.
Wednesday's top analyst upgrades and downgrades included Altria, Apple, Caterpillar, Citigroup, JPMorgan, Nikola, Nokia, Novavax, Transocean, Valero Energy, Walt Disney and Wells Fargo.
If investors have learned one thing over time, it is that it can be very painful when a company announces that it is cutting its dividend. 24/7 Wall St. has screened out…
With new e-cigarette lawsuits, Juul is anything but the jewel in the Altria crown.
247sarah Altria’s attempts to diversify have soured and its stock is lagging, but the company has pricing power and pays a solid dividend.
247sarah Counting out a tobacco company has never proved to be a good bet over the long term. Will this time be different?
Cigarette smoking is falling out of favor but Altria could still appeal to investors as it looks to tobacco alternatives.
Altria wants to diversify into e-cigarettes and legal pot, but faces regulatory action, patent litigation and coronavirus-related setbacks.
U.K. tobacco giant Imperial Brands has slashed its dividend. Will American tobacco companies follow suit?
When the economy began to face an instant recession from the coronavirus, even before the name COVID-19 became labeled a pandemic, the phenomena of buying defensive stocks was thrown out the window.…
Altria's share price is falling. Its investments have been busts, and hedge funds and shareholders are getting cranky. Even the dividend hasn't made investors happy.
Altria’s investments in Juul and Cronos Group weigh on investor sentiment even though core tobacco business looks strong.
247sarah COVID-19 has already beaten up tobacco giant Altria but things may be getting even worse as Juul, in which it has a stake, is facing fresh problems.
